BCM
IRD

Boxer Capital Management’s Opus Genetics IRD Stock Holding History

Boxer Capital Management’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.6M Buy
2,815,000
+565,000
+25% +$2.64M 0.87% 24
2026
Q1 		$10.2M Buy
+2,250,000
New +$7.78M 1.34% 20

Other funds holding IRD

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Boxer Capital Management's IRD Position: Q2 2026 in Review

Boxer Capital Management increased its Opus Genetics (IRD) stake by 25% in Q2 2026, buying an estimated $2.64M and bringing the position to 2,815,000 shares worth $11.6M. The position accounts for 0.87% of the portfolio, ranked #24.

Boxer Capital Management first reported a position in IRD in Q1 2026 and has held it in 2 quarters since. 103 funds tracked by Wall St. Rank hold IRD as of Q2 2026.

  • Boxer Capital Management held 2,815,000 shares of Opus Genetics worth $11.6M as of Q2 2026.
  • Boxer Capital Management bought 565,000 Opus Genetics shares in Q2 2026, an estimated $2.64M.
  • Opus Genetics made up 0.87% of Boxer Capital Management's portfolio in Q2 2026, its #24 holding.
  • Boxer Capital Management first reported a position in Opus Genetics in Q1 2026 and has held it in 2 quarters since.
  • 103 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2026.

Based on Boxer Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.